ChromoCure, Inc. makes key appointment to Medical Advisory Board and Business Development Team
Posted on: Tuesday, 22 September 2009, 08:30 CDT
Trained and Board Certified Surgical Pathologist/Dermatopathologist. He brings a 20 year career of experience as Medical Director/ Administrator/Surgical Pathologist and Dermatopathologist in a privately owned commercial Pathology Laboratory. His early research interests were involved in Tissue culture and Cytogenetics. He holds unrestricted licenses to practice in state of NY, NJ,
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
SOURCE ChromoCure, Inc.
Source: PR Newswire
Related Articles
- Compendia Bioscience Announces the Release of Oncomine 4 Research Edition
- Insurer FM Global Releases New Sustainability Research Showing Ways Building Owners and Designers Can Reduce Carbon Emissions Due to Fire and Natural Disaster Risks
- Peanut Labs Executive Appointed to Advertising Research Foundation's Online Research Quality Council
- Accuray Exceeds 4,000 Lung Cancer Patients Treated With CyberKnife(R) System
- New Prostate Cancer Care Legislation Would Fund Lifesaving Imaging Research and Save Health Care System $5 Billion Annually
- BIOIDENT Announces First Complete Lab-on-a-Chip System Based on Printed Semiconductor Technology
- Report in CANCER Describes BSD Medical's Premier System As 'Feasible and Suitable' for Uses in Treating Soft Tissue Sarcomas
- Cardinal Health Signs Agreement With the University of Texas M.D. Anderson Cancer Center for Its Alaris(R) System
- Outsmarting Cancer; Vaccine Trials Probe Immune System's Potential to Attack Recurring Cells
- The Acceptability of a Small Intrauterine Progestogen-Releasing System for Continuous Combined Hormone Therapy in Early Postmenopausal Women
 |
 |
User Comments (0)
RSS Feeds